Low-Normal Thyroid Function and Novel Cardiometabolic Biomarkers

Nutrients

Lynnda J.N. van Tienhoven-Wind¹ 

[1] Department of Endocrinology, University of Groningen and University Medical Center Groningen, Groningen, AV Groningen 19713, the Netherlands; E-Mail

关键词: bilirubin;    biomarkers;    cardiovascular disease;    cholesteryl ester transfer;    dyslipidemia;    lipids;    metabolic syndrome;    non-alcoholic fatty liver disease;    subclinical hypothyroidism;    thyroid hormones;   

DOI  :  10.3390/nu7021352

来源: mdpi

【 摘 要 】

The concept is emerging that low-normal thyroid function, i.e., either higher thyroid-stimulating hormone or lower free thyroxine levels within the euthyroid reference range, could contribute to the development of atherosclerotic cardiovascular disease. It is possible that adverse effects of low-normal thyroid function on cardiovascular outcome may be particularly relevant for specific populations, such as younger people and subjects with high cardiovascular risk. Low-normal thyroid function probably relates to modest increases in plasma total cholesterol, low density lipoprotein cholesterol, triglycerides and insulin resistance, but effects on high density lipoprotein (HDL) cholesterol and non-alcoholic fatty liver disease are inconsistent. Low-normal thyroid function may enhance plasma cholesteryl ester transfer, and contribute to an impaired ability of HDL to inhibit oxidative modification of LDL, reflecting pro-atherogenic alterations in lipoprotein metabolism and HDL function, respectively. Low-normal thyroid function also confers lower levels of bilirubin, a strong natural anti-oxidant. Remarkably, all these effects of low-normal thyroid functional status appear to be more outspoken in the context of chronic hyperglycemia and/or insulin resistance. Collectively, these data support the concept that low-normal thyroid function may adversely affect several processes which conceivably contribute to the pathogenesis of atherosclerotic cardiovascular disease, beyond effects on conventional lipoprotein measures.

【 授权许可】

CC BY   
© 2015 by the authors; licensee MDPI, Basel, Switzerland.